Nathan Haas - 11 Nov 2022 Form 3 Insider Report for Vitro Biopharma, Inc.

Role: Chief Financial Officer
Signature: /s/ Nathan Haas
Issuer symbol: N/A
Transactions as of: 11 Nov 2022
Net transactions value: $0
Form type: 3
Filing time: 14 Nov 2022, 13:33:08 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding		Common Stock						1,881,299	11 Nov 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding		Employee Stock Option (Right to Buy)							11 Nov 2022	Common Stock	1,000,000	$0.5000	Direct	F1
holding		Employee Stock Option (Right to Buy)							11 Nov 2022	Common Stock	500,000	$0.5000	Direct	F2
holding		Warrant (Right to Buy)							11 Nov 2022	Common Stock	120,000	$0.5000	Direct
holding		Warrant (Right to Buy)							11 Nov 2022	Common Stock	120,000	$1.00	Direct
holding		Warrant (Right to Buy)							11 Nov 2022	Common Stock	400,000	$0.5000	Direct
holding		Warrant (Right to Buy)							11 Nov 2022	Common Stock	400,000	$1.00	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option became exercisable as to 200,000 shares on August 1, 2022, and will become exercisable as to (i) 200,000 shares on August 1, 2023, (ii) 200,000 shares on August 1, 2024, (iii) 200,000 shares on August 1, 2025, and (iv) 200,000 shares on August 1, 2026.
F2	The option became exercisable as to 100,000 shares on October 1, 2022, and will become exercisable as to (i) 100,000 shares on October 1, 2023, (ii) 100,000 shares on October 1, 2024, (iii) 100,000 shares on October 1, 2025, and (iv) 100,000 shares on October 1, 2026.